cb-103
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 5, 2017 (NCT03422679)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Adenoid Cystic · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Leukemia · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
NOTCH2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05774899 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2023 | Adenoid Cystic Carcinoma Research Foundation, Cellestia Biotech AG, Harvard University |
| NCT05464836 | Phase 2 | Dec 30, 2022 | University of Texas at Houston |
| NCT04714619 | Phase 2 | May 6, 2021 | Cellestia Biotech AG, MedSIR, University of Valencia |
| NCT03422679 | Phase 1/Phase 2 (Phase 2) | Dec 5, 2017 | Cellestia Biotech AG |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellestia Biotech AG | For profit | 3 | 1 | 1 | 2017 |
| Adenoid Cystic Carcinoma Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| MedSIR | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Valencia | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1